184 related articles for article (PubMed ID: 22136493)
1. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme.
Deng YF; Aluko RE; Jin Q; Zhang Y; Yuan LJ
Pharm Biol; 2012 Apr; 50(4):401-6. PubMed ID: 22136493
[TBL] [Abstract][Full Text] [Related]
2. Size of the aliphatic chain of sodium houttuyfonate analogs determines their affinity for renin and angiotensin I converting enzyme.
Yuan L; Wu J; Aluko RE
Int J Biol Macromol; 2007 Aug; 41(3):274-80. PubMed ID: 17467790
[TBL] [Abstract][Full Text] [Related]
3. Evaluating molecular mechanism of hypotensive peptides interactions with renin and angiotensin converting enzyme.
He R; Aluko RE; Ju XR
PLoS One; 2014; 9(3):e91051. PubMed ID: 24603692
[TBL] [Abstract][Full Text] [Related]
4. Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition.
Ottaviani JI; Actis-Goretta L; Villordo JJ; Fraga CG
Biochimie; 2006; 88(3-4):359-65. PubMed ID: 16330143
[TBL] [Abstract][Full Text] [Related]
5. Enzyme inhibition kinetics and molecular interactions of patatin peptides with angiotensin I-converting enzyme and renin.
Fu Y; Alashi AM; Young JF; Therkildsen M; Aluko RE
Int J Biol Macromol; 2017 Aug; 101():207-213. PubMed ID: 28300587
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity.
Waeber B; Nussberger J; Juillerat L; Brunner HR
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S53-9. PubMed ID: 2483430
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Ailanthus excelsa (Roxb) (Simaroubaceae).
Loizzo MR; Said A; Tundis R; Rashed K; Statti GA; Hufner A; Menichini F
Phytother Res; 2007 Jan; 21(1):32-6. PubMed ID: 17072829
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism.
Jiménez-Ferrer E; Badillo FH; González-Cortazar M; Tortoriello J; Herrera-Ruiz M
J Ethnopharmacol; 2010 Jul; 130(2):340-6. PubMed ID: 20488233
[TBL] [Abstract][Full Text] [Related]
9. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
[TBL] [Abstract][Full Text] [Related]
11. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
Schalekamp MA; Derkx FH; van den Meiracker AH
J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
[TBL] [Abstract][Full Text] [Related]
12. Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system.
Guang C; Phillips RD; Jiang B; Milani F
Arch Cardiovasc Dis; 2012; 105(6-7):373-85. PubMed ID: 22800722
[TBL] [Abstract][Full Text] [Related]
13. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA
J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of renin: an updated review of the development of renin inhibitors.
Li YC
Curr Opin Investig Drugs; 2007 Sep; 8(9):750-7. PubMed ID: 17729187
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effect of caffeic acid and its analogs through dual renin-angiotensin-aldosterone system inhibition.
Bhullar KS; Lassalle-Claux G; Touaibia M; Rupasinghe HP
Eur J Pharmacol; 2014 May; 730():125-32. PubMed ID: 24631256
[TBL] [Abstract][Full Text] [Related]
16. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition.
Hingorani AD; Jia H; Stevens PA; Hopper R; Dickerson JE; Brown MJ
J Hypertens; 1995 Dec; 13(12 Pt 2):1602-9. PubMed ID: 8903618
[TBL] [Abstract][Full Text] [Related]
18. STRUCTURAL CHARACTERISTICS AND ANTIHYPERTENSIVE EFFECTS OF ANGIOTENSIN-I-CONVERTING ENZYME INHIBITORY PEPTIDES IN THE RENIN-ANGIOTENSIN AND KALLIKREIN KININ SYSTEMS.
Manoharan S; Shuib AS; Abdullah N
Afr J Tradit Complement Altern Med; 2017; 14(2):383-406. PubMed ID: 28573254
[TBL] [Abstract][Full Text] [Related]
19. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
20. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
